Nicotine
Discover related
4 sources
Collated from PsychonautWiki, TripSit, Pharmacology, DrugCentral. Where sources differ (e.g. dosing), Compare shows them side by side.
Also known as NicotinePW
The nicotine metabolite N-nitrosonornicotine is classified as a IARC Group 1 carcinogen Nicotine in the mouth and stomach can react to form N-nitrosonornicotine (NNN),[1] a known type 1 carcinogen,[2] suggesting that consumption of non-tobacco forms of nicotine may still play a role in carcinogenesis.[3] This suggests that even oral nicotine replacement therapy products could theoretically contribute to cancer risk.PW
Buccal
Route dataPsychonautWiki
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 0.2 mg | 0.5–2 mg | 2–4 mg | 4–6 mg | 6 mg+ |
| Onset | 3–15 minutes |
|---|---|
| Come-up | 3–15 minutes |
| Peak | 5–20 minutes |
| Offset | 1–2 hours |
| Total | 45–90 minutes |
| After-effects | 2–6 hours |
Oral
Route dataPsychonautWiki
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 0.2 mg | 1–3 mg | 3–5 mg | 5–7 mg | 7 mg+ |
| Onset | 20–40 minutes |
|---|---|
| Come-up | 60–90 minutes |
| Peak | 60–90 minutes |
| Offset | 2.5–3.5 hours |
| Total | 5–7 hours |
| After-effects | 2–4 hours |
Smoked
Route dataPsychonautWiki
| Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| 0.2 mg | 0.3–0.8 mg | 0.8–1.5 mg | 1.5–3.5 mg | 3.5 mg+ |
| Onset | 5–20 seconds |
|---|---|
| Come-up | 5–10 seconds |
| Peak | 2–5 minutes |
| Offset | 1–2 hours |
| Total | 1–3 hours |
| After-effects | 1–3 hours |
🧬 Receptor activityDC
| Target | Action | Affinity | Source | |
|---|---|---|---|---|
| Neuronal acetylcholine receptor; alpha4/beta2 (CHRNB2) | Agonist | 8.56 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor; alpha4/beta2 (CHRNB2) ActionAgonist Affinity8.56 Ki SourceDRUGCENTRAL |
| Potassium voltage-gated channel subfamily D member 3 (Kcnd3) | Blocker | 7.4 IC50 | DRUGCENTRAL | TargetPotassium voltage-gated channel subfamily D member 3 (Kcnd3) ActionBlocker Affinity7.4 IC50 SourceDRUGCENTRAL |
| Transient receptor potential cation channel subfamily A member 1 (TRPA1) | Activator | 4.8 EC50 | DRUGCENTRAL | TargetTransient receptor potential cation channel subfamily A member 1 (TRPA1) ActionActivator Affinity4.8 EC50 SourceDRUGCENTRAL |
| Acetylcholine receptor (CHRNA1) | — | 5.2 Ki | DRUGCENTRAL | TargetAcetylcholine receptor (CHRNA1) Action— Affinity5.2 Ki SourceDRUGCENTRAL |
| Acetylcholine receptor subunit alpha (CHRNA1) | — | 4.64 IC50 | DRUGCENTRAL | TargetAcetylcholine receptor subunit alpha (CHRNA1) Action— Affinity4.64 IC50 SourceDRUGCENTRAL |
| Acetylcholine receptor subunit beta-like 2 (nAChRbeta2) | — | 5.57 Ki | DRUGCENTRAL | TargetAcetylcholine receptor subunit beta-like 2 (nAChRbeta2) Action— Affinity5.57 Ki SourceDRUGCENTRAL |
| Acetylcholine receptor subunit delta (chrnd) | — | 9 Ki | DRUGCENTRAL | TargetAcetylcholine receptor subunit delta (chrnd) Action— Affinity9 Ki SourceDRUGCENTRAL |
| Acetylcholine receptor; alpha1/beta1/delta/gamma (CHRNA1) | — | 5.83 Ki | DRUGCENTRAL | TargetAcetylcholine receptor; alpha1/beta1/delta/gamma (CHRNA1) Action— Affinity5.83 Ki SourceDRUGCENTRAL |
| Acetylcholine-binding protein | — | 7.2 Ki | DRUGCENTRAL | TargetAcetylcholine-binding protein Action— Affinity7.2 Ki SourceDRUGCENTRAL |
| Cytochrome P450 2A6 (CYP2A6) | — | 5.356 IC50 | DRUGCENTRAL | TargetCytochrome P450 2A6 (CYP2A6) Action— Affinity5.356 IC50 SourceDRUGCENTRAL |
| Lycopene cyclase (crtY) | — | 5.32 IC50 | DRUGCENTRAL | TargetLycopene cyclase (crtY) Action— Affinity5.32 IC50 SourceDRUGCENTRAL |
| Muscarinic acetylcholine receptor (Chrm1) | — | 4.55 IC50 | DRUGCENTRAL | TargetMuscarinic acetylcholine receptor (Chrm1) Action— Affinity4.55 IC50 SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor (Chrna3) | — | 11 Kd | DRUGCENTRAL | TargetNeuronal acetylcholine receptor (Chrna3) Action— Affinity11 Kd SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor subunit alpha-2 (Chrna2) | — | 7.92 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor subunit alpha-2 (Chrna2) Action— Affinity7.92 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor subunit alpha-3 (Chrna3) | — | 7.33 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor subunit alpha-3 (Chrna3) Action— Affinity7.33 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor subunit alpha-4 (Chrna4) | — | 9.03 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor subunit alpha-4 (Chrna4) Action— Affinity9.03 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor subunit alpha-7 (CHRNA7) | — | 5.39 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor subunit alpha-7 (CHRNA7) Action— Affinity5.39 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor subunit alpha-9 (Chrna9) | — | 8.3 Kd | DRUGCENTRAL | TargetNeuronal acetylcholine receptor subunit alpha-9 (Chrna9) Action— Affinity8.3 Kd SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor subunit beta-4 (Chrnb4) | — | 7.14 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor subunit beta-4 (Chrnb4) Action— Affinity7.14 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor; alpha2/beta2 (Chrna2) | — | 8.26 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor; alpha2/beta2 (Chrna2) Action— Affinity8.26 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor; alpha2/beta4 (CHRNB4) | — | 7.15 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor; alpha2/beta4 (CHRNB4) Action— Affinity7.15 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 (CHRNB2) | — | 7.07 IC50 | DRUGCENTRAL | TargetNeuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 (CHRNB2) Action— Affinity7.07 IC50 SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor; alpha3/beta2 (Chrna3) | — | 9 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor; alpha3/beta2 (Chrna3) Action— Affinity9 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor; alpha3/beta4 (Chrna3) | — | 6.7 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor; alpha3/beta4 (Chrna3) Action— Affinity6.7 Ki SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor; alpha4/beta2 (Chrna4) | — | 9.4 Kd | DRUGCENTRAL | TargetNeuronal acetylcholine receptor; alpha4/beta2 (Chrna4) Action— Affinity9.4 Kd SourceDRUGCENTRAL |
| Neuronal acetylcholine receptor; alpha4/beta4 (Chrna4) | — | 8.26 Ki | DRUGCENTRAL | TargetNeuronal acetylcholine receptor; alpha4/beta4 (Chrna4) Action— Affinity8.26 Ki SourceDRUGCENTRAL |
| Nicotinic acetylcholine receptor alpha 5 subunit (nAChRalpha5) | — | 5.61 Ki | DRUGCENTRAL | TargetNicotinic acetylcholine receptor alpha 5 subunit (nAChRalpha5) Action— Affinity5.61 Ki SourceDRUGCENTRAL |
| Potassium voltage-gated channel subfamily D member 3 (KCND3) | — | 7.4 IC50 | DRUGCENTRAL | TargetPotassium voltage-gated channel subfamily D member 3 (KCND3) Action— Affinity7.4 IC50 SourceDRUGCENTRAL |
| Serotonin 3 (5-HT3) receptor (HTR3E) | — | 4.15 Ki | DRUGCENTRAL | TargetSerotonin 3 (5-HT3) receptor (HTR3E) Action— Affinity4.15 Ki SourceDRUGCENTRAL |
| Soluble acetylcholine receptor | — | 7.52 Ki | DRUGCENTRAL | TargetSoluble acetylcholine receptor Action— Affinity7.52 Ki SourceDRUGCENTRAL |
| Transient receptor potential cation channel subfamily A member 1 (Trpa1) | — | 5 EC50 | DRUGCENTRAL | TargetTransient receptor potential cation channel subfamily A member 1 (Trpa1) Action— Affinity5 EC50 SourceDRUGCENTRAL |
Mechanism of actionPH
Nicotine is a stimulant drug that acts as an agonist at nicotinic acetylcholine receptors. These are ionotropic receptors composed up of five homomeric or heteromeric subunits. In the brain, nicotine binds to nicotinic acetylcholine receptors on dopaminergic neurons in the cortico-limbic pathways. This causes the channel to open and allow conductance of multiple cations including sodium, calcium, and potassium. This leads to depolarization, which activates voltage-gated calcium channels and allows more calcium to enter the axon terminal. Calcium stimulates vesicle trafficking towards the plasma membrane and the release of dopamine into the synapse. Dopamine binding to its receptors is responsible the euphoric and addictive properties of nicotine. Nicotine also binds to nicotinic acetylcholine receptors on the chromaffin cells in the adrenal medulla. Binding opens the ion channel allowing influx of sodium, causing depolarization of the cell, which activates voltage-gated calcium channels. Calcium triggers the release of epinephrine from intracellular vesicles into the bloodstream, which causes vasoconstriction, increased blood pressure, increased heart rate, and increased blood sugar.
Nicotine is a ganglionic (nicotinic) cholinergic-receptor agonist. The pharmacologic actions of nicotine are complex and include a variety of effects mediated by stereospecific binding to receptors in autonomic ganglia, the adrenal medulla, the neuromuscular junction, and the brain.
The principal pharmacologic effect of small doses of nicotine is initial, transient stimulation of autonomic ganglia; large doses or prolonged neuronal receptor exposure to nicotine results in subsequent persistent depression of receptor activity. Although nicotine has similar dose-related effects at the myoneural (neuromuscular) junction, rapidly developing skeletal muscle paralysis obscures the stimulant phase. The muscle-relaxant properties of nicotine may be mediated through stimulation of Renshaw cells and pulmonary afferent nerves, which results in inhibition of skeletal muscle motor activity; such relaxant effects may contribute to the behavior-reinforcing effects of the drug. Small doses of nicotine directly stimulate sympathetic ganglia and facilitate neurotransmission; however, large doses produce initial ganglionic stimulation, which is quickly followed by inhibition of neurotransmission.
PharmacodynamicsPH
Nicotine, the primary alkaloid in tobacco products binds stereo-selectively to nicotinic-cholinergic receptors on autonomic ganglia, the adrenal medulla, neuromuscular junctions and in the brain. Nicotine exerts two effects, a stimulant effect exerted at the locus ceruleus and a reward effect in the limbic system. Itranvenous administration of nicotine causes release of acetylcholine, norepinephrine, dopamine, serotonine, vasopressin, beta-endorphin and ACTH. Nicotine is a highly addictive substance. Nicotine also induces peripheral vasoconstriction, tachycardia and elevated blood pressure. Nicotine inhalers and patches are used to treat smoking withdrawl syndrome. Nicotine is classified as a stimulant of autonomic ganglia.
Pharmacokinetics
Half-lifePH
Cotinine has a half life of 15-20 hours, while nicotine has a half life of 1-3 hours
Plasma concentrations of nicotine appear to decline in a biphasic manner. The half-life of nicotine in the initial phase is reportedly about 2-3 minutes and the half-life in the terminal phase reportedly averages about 2 hours (range: 1-4 hours).
Following removal of a transdermal system of nicotine, plasma nicotine concentrations decline with an apparent half-life averaging 3-6 hours, which exceeds that of nicotine given iv; the slow decline in plasma nicotine concentrations following removal of a transdermal system appears to result from continued absorption of residual drug in the skin.
Cotinine is the major metabolite /of nicotine/ and has a plasma half-life of about 10-40 hours.
... Following the administration of 0.1 mg nicotine/kg (labeled in 2-(14)C-pyrrolidone) to rats ... radioactivity due to nicotine and cotinine was detected in substantial amounts in plasma samples. Nicotine disappearance was biexponential, with an elimination half life of 1.0 hour. Cotinine appeared as the major metabolite in plasma and had elimination half life of 5.2 hours.
AbsorptionPH
Absorption of nicotine through the buccal mucosa is relatively slow and the high and rapid rise followed by the decline in nicotine arterial plasma concentrations seen with cigarette smoking are not achieved with the inhaler. About 10% of absorbed nicotine is excreted unchanged in urine.
About 10% of the nicotine absorbed is excreted unchanged in the urine.
2 to 3 L/kg
1.2 L/min [healthy adult smoker]
Nicotine is readily absorbed from respiratory tract, buccal mucous membranes, and skin. ... Both nicotine and its metabolites are rapidly eliminated by the kidneys. The rate of urinary excretion of nicotine is dependent upon pH of urine; excretion diminishes when urine is alkaline. Nicotine is also excreted in milk of lactating women who smoke. Milk of heavy smokers may contain 0.5 mg/L. ...Apparently the gastric absorption of nicotine from tobacco taken by mouth is delayed because of slowed gastric emptying, so that vomiting may remove much of the tobacco remaining in GI tract.
Although nicotine is absorbed rapidly over large section of GI tract, absorption of n-oxide is limited to area relatively high in intestine. n-Oxide is reduced to nicotine in gut and nicotine produced is absorbed low enough in GI tract to avoid first pass phenomenon.
MetabolismPH
Primarily hepatic, cotinine is the primary metabolite.
Metabolism of nicotine is qualitatively similar following buccal absorption from nicotine polacrilex gum or nicotine oral inhalation and from oral inhalation of cigarette smoke, and reportedly following application of nicotine transdermal systems. Although the exact metabolic fate of nicotine is not clearly established, the drug is metabolized extensively to more than 20 metabolites, but principally in the liver via oxidation of the alpha-carbon and N-oxidation of the pyrrolidine ring to cotinine and nicotine-1'-N-oxide, respectively. These metabolites are not pharmacologically active in humans at blood concentrations attained during cigarette smoking; however, cotinine has been reported to be pharmacologically active in animals, but its potency at equivalent molar concentrations is substantially less than that of nicotine. ... Nicotine may also be metabolized to a lesser extent in the kidneys and lungs.
Nicotine-1'-N-oxide is reduced to nicotine by bacterial flora in the large intestine via an N-oxide reductase system and subsequently undergoes enterohepatic circulation and repeat metabolism in the liver.
Toxicologically, it is of interest that /the microsomal flavin-containing monooxygenase/ is responsible for the oxidation of nicotine to nicotine-1'-N-oxide, whereas the oxidation of nicotine to cotinine is catalyzed by two enzymes acting in sequence: P450 and a soluble aldehyde dehydrogenase. Thus, nicotine is metabolized by two different routes, the relative contributions of which may vary with both the extrinsic and intrinsic factors.
In vitro studies with rabbit liver microsomes, /NADPH/, and O2, indicated that metabolism of nicotine proceeded through hydroxylation to 5-(3'-pyridyl)-n-methylpyrrolidine-2-ol; oxidation to cotinine; and deamidation of cotinine to 4-(3'-pyridyl)-4-methylamino-butyric acid. No carbon dioxide was observed.
For more Metabolism/Metabolites (Complete) data for NICOTINE (11 total), please visit the HSDB record page.
Protein bindingPH
Less than 5%
Plan a dose of Nicotine
Loading the fact-sheet…
Logging a dose needs somewhere to keep it. Start a free session — no signup; it and everything in it expire in 7 days.
External links
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.